End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.77 CNY | -1.99% | -1.34% | -37.18% |
26/04 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
25/04 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
ETFs positioned on Walvax Biotechnology Co., Ltd.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.09% | 2 M€ | -12.41% | - | |
0.54% | 2 M€ | -14.14% | ||
0.23% | 35 M€ | -5.85% | - | |
0.01% | 4 M€ | -4.41% | - | |
0.00% | 112 M€ | +4.06% | - | |
0.00% | 153 M€ | +6.72% | - | |
0.00% | 454 M€ | +8.54% | - | |
0.00% | 2,867 M€ | +9.57% | - | |
0.00% | 32 M€ | +7.48% | - | |
0.00% | 391 M€ | +8.67% | - | |
0.00% | 34 M€ | +8.24% | - | |
0.00% | 39 M€ | +5.65% | - | |
0.00% | 306 M€ | +5.68% | - | |
0.00% | 34 M€ | +3.39% | - | |
0.00% | 105 M€ | +3.54% | - | |
0.00% | 17 M€ | +2.80% | - | |
0.00% | 7 M€ | +5.02% | - | |
0.00% | 54 M€ | +0.54% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.18% | 3.34B | |
-2.10% | 89.08B | |
+2.76% | 40.9B | |
-12.92% | 32.25B | |
+54.69% | 25.14B | |
-16.51% | 15.39B | |
-8.27% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- 300142 Stock
- Funds and ETFs Walvax Biotechnology Co., Ltd.